Antibody Drug Conjugate Market Revenue 2024 to 2034
Antibody Drug Conjugate Market Revenue 2024 to 2034
The global antibody drug conjugate (ADC) market size is projected to grow from USD 13.51 billion in 2025 to USD 29.9 billion by 2034, at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2034.
Report ID: 10192
|
Format: Databook
|
Published: August 2025
|
Delivery: Immediate
Download Sample
Customisation Request
Revenue,
USD USD 12.36 Bn
Forecast Year,
USD USD 29.9 Bn
CAGR, 2025 -
9.23%
Report Coverage
Worldwide
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
Antibody Drug Conjugate Market Size Analysis
Antibody Drug Conjugate Market Size By Application 2024 to 2034 (USD )
| Application | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood Cancer | 3.71 | 4.06 | 4.44 | 4.86 | 5.31 | 5.81 | 6.36 | 6.96 | 7.61 | 8.33 | 9.11 |
| Breast Cancer | 3.46 | 3.78 | 4.14 | 4.52 | 4.95 | 5.41 | 5.92 | 6.47 | 7.07 | 7.73 | 8.46 |
| Urothelial Cancer & Bladder Cancer | 2.72 | 2.97 | 3.24 | 3.53 | 3.86 | 4.21 | 4.59 | 5.01 | 5.47 | 5.97 | 6.51 |
| Other Cancer | 2.47 | 2.69 | 2.93 | 3.19 | 3.48 | 3.79 | 4.12 | 4.49 | 4.89 | 5.32 | 5.80 |
Antibody Drug Conjugate Market Size By Product 2024 to 2034 (USD )
| Product | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Kadcyla | 2.22 | 2.44 | 2.67 | 2.92 | 3.20 | 3.50 | 3.83 | 4.19 | 4.59 | 5.02 | 5.50 |
| Enhertu | 2.10 | 2.30 | 2.52 | 2.75 | 3.01 | 3.30 | 3.61 | 3.95 | 4.32 | 4.72 | 5.17 |
| Adcetris | 1.98 | 2.16 | 2.35 | 2.57 | 2.80 | 3.06 | 3.33 | 3.64 | 3.97 | 4.33 | 4.72 |
| Padcev | 1.73 | 1.89 | 2.06 | 2.25 | 2.46 | 2.68 | 2.93 | 3.19 | 3.49 | 3.81 | 4.15 |
| Trodelvy | 1.61 | 1.76 | 1.92 | 2.10 | 2.30 | 2.52 | 2.75 | 3.01 | 3.30 | 3.61 | 3.94 |
| Polivy | 1.48 | 1.62 | 1.76 | 1.92 | 2.09 | 2.28 | 2.48 | 2.70 | 2.95 | 3.21 | 3.50 |
| Others | 1.24 | 1.35 | 1.47 | 1.60 | 1.74 | 1.89 | 2.06 | 2.24 | 2.44 | 2.66 | 2.90 |
Antibody Drug Conjugate Market Size By Target 2024 to 2034 (USD )
| Target | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HER2 | 4.33 | 4.73 | 5.17 | 5.66 | 6.19 | 6.77 | 7.40 | 8.09 | 8.85 | 9.67 | 10.58 |
| CD22 | 3.09 | 3.38 | 3.70 | 4.04 | 4.42 | 4.83 | 5.29 | 5.78 | 6.32 | 6.91 | 7.56 |
| CD30 | 2.47 | 2.70 | 2.94 | 3.21 | 3.50 | 3.81 | 4.16 | 4.54 | 4.95 | 5.40 | 5.89 |
| Others | 2.47 | 2.69 | 2.94 | 3.20 | 3.49 | 3.81 | 4.15 | 4.52 | 4.93 | 5.37 | 5.86 |
Antibody Drug Conjugate Market Size By Technology 2024 to 2034 (USD )
| Technology | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Type | 4.94 | 5.40 | 5.91 | 6.46 | 7.06 | 7.72 | 8.43 | 9.22 | 10.08 | 11.02 | 12.04 |
| Linker Technology Type | 3.71 | 4.05 | 4.43 | 4.84 | 5.29 | 5.78 | 6.31 | 6.90 | 7.53 | 8.23 | 9.00 |
| Payload Technology | 3.71 | 4.04 | 4.41 | 4.81 | 5.25 | 5.73 | 6.25 | 6.81 | 7.43 | 8.11 | 8.85 |
Antibody Drug Conjugate Market Size By Region 2024 to 2034 (USD )
| Region | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | 4.94 | 5.40 | 5.91 | 6.46 | 7.06 | 7.72 | 8.43 | 9.22 | 10.08 | 11.02 | 12.04 |
| Asia Pacific | 3.09 | 3.38 | 3.69 | 4.04 | 4.41 | 4.82 | 5.27 | 5.76 | 6.30 | 6.89 | 7.53 |
| Europe | 2.47 | 2.70 | 2.94 | 3.21 | 3.50 | 3.82 | 4.17 | 4.55 | 4.97 | 5.42 | 5.92 |
| Latin America | 1.24 | 1.35 | 1.47 | 1.61 | 1.75 | 1.91 | 2.09 | 2.28 | 2.48 | 2.71 | 2.96 |
| Middle East and Africa | 0.62 | 0.67 | 0.73 | 0.80 | 0.87 | 0.94 | 1.02 | 1.11 | 1.21 | 1.32 | 1.43 |
Antibody Drug Conjugate Market
Proceed To Buy
Proceed To CheckoutMake Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Quick Contact
- NA : +1 804 441 9344
- APAC : +91 9356 9282 04
- EU : +44 7782 560 738
- sales@precedenceresearch.com
